Serotonergic drugs and valvular heart disease
暂无分享,去创建一个
[1] R. Rothman,et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. , 1999, Circulation.
[2] R. Rothman,et al. 1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain , 2001, Neuropsychopharmacology.
[3] Daniel Hoyer,et al. Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.
[4] W. Weiger. SEROTONERGIC MODULATION OF BEHAVIOUR: A PHYLOGENETIC OVERVIEW , 1997, Biological reviews of the Cambridge Philosophical Society.
[5] M. Reis,et al. Serum Concentrations of Fluoxetine in the Clinical Treatment Setting , 2001, Therapeutic drug monitoring.
[6] R. Califf,et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. , 2001, The American journal of cardiology.
[7] M. Mcgoon,et al. Obesity drugs and the heart. , 1999, Current problems in cardiology.
[8] B. Roth,et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.
[9] B. Roth. Drugs and valvular heart disease. , 2007, The New England journal of medicine.
[10] R. Rothman,et al. Therapeutic and adverse actions of serotonin transporter substrates. , 2002, Pharmacology & therapeutics.
[11] V. Rigolin,et al. Appetite suppressants and valvular heart disease. , 2002, Current opinion in cardiology.
[12] R. N. Brogden,et al. Fenfluramine , 2012, Drugs.
[13] D. Heal,et al. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.
[14] U. Bredberg,et al. Pharmacokinetics of methysergide and its metabolite methylergometrine in man , 2004, European Journal of Clinical Pharmacology.
[15] F. Artigas,et al. Simultaneous Effects of p‐Chloroamphetamine, d‐Fenfluramine, and Reserpine on Free and Stored 5‐Hydroxytryptamine in Brain and Blood , 1992, Journal of neurochemistry.
[16] K. Rice,et al. Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.
[17] C. Schreiner,et al. Sound-induced seizures in serotonin 5-HT2c receptor mutant mice , 1997, Nature Genetics.
[18] J. Van Dorpe,et al. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. , 1996, The Journal of heart valve disease.
[19] R. Rothman,et al. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications , 2000, Synapse.
[20] R. Rothman,et al. Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels , 2008, Journal of Pharmacology and Experimental Therapeutics.
[21] J. Pouysségur,et al. Serotonin stimulates DNA synthesis in fibroblasts acting through 5–HT1B receptors coupled to a Gi-protein , 1988, Nature.
[22] A. Bossuyt,et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. , 2007, European heart journal.
[23] K. Otani,et al. Plasma concentrations of trazodonb and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[24] Michael H. Baumann,et al. (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters , 2003, Journal of Pharmacology and Experimental Therapeutics.
[25] Brian M. Smith,et al. The potential use of selective 5-HT2C agonists in treating obesity , 2006, Expert opinion on investigational drugs.
[26] E. D. de Vries,et al. Profiling of tryptophan-related plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. , 2001, Clinical chemistry.
[27] R. Horowski,et al. Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis , 2006, Clinical neuropharmacology.
[28] L. Tecott,et al. Mouse Genetic Approaches to Feeding Regulation: Serotonin 5-HT2C Receptor Mutant Mice , 2003, CNS Spectrums.
[29] G. Kennett,et al. Comparative effects of continuous infusion of mCPP, Ro 60‐0175 and d‐fenfluramine on food intake, water intake, body weight and locomotor activity in rats , 2000, British journal of pharmacology.
[30] O. Spigset,et al. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine. , 2007, Basic & clinical pharmacology & toxicology.
[31] E. Pettersson. Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro. , 1995, European journal of pharmacology.
[32] P. Franken,et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. , 2007, The American journal of cardiology.
[33] L. Weinrauch,et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.
[34] R. Porter,et al. Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.
[35] E. D. de Vries,et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. , 2000, Clinical chemistry.
[36] E. Gouzoulis-Mayfrank,et al. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? , 2006, Addiction.
[37] K. Otani,et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.
[38] S. Garattini. Biological actions of drugs affecting serotonin and eating. , 1995, Obesity research.
[39] M. Baumann,et al. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats , 1993, Neuropharmacology.
[40] B. Corya,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.
[41] R. Ings,et al. Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.
[42] S. Garattini,et al. Effect of some anorectic agents on the uptake and release of 5‐hydroxytryptamine by blood platelets of rats , 1975, The Journal of pharmacy and pharmacology.
[43] P. Hopkins,et al. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals , 2008, BMC medicine.
[44] A H Chester,et al. Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents. , 2000, The Journal of heart valve disease.
[45] V. Setola,et al. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen–phen’ , 2005, Expert opinion on drug metabolism & toxicology.
[46] S. Garattini,et al. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days , 2004, European Journal of Clinical Pharmacology.
[47] L. Tecott,et al. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.
[48] Y. Loke,et al. BMC Clinical Pharmacology BioMed Central BMC 22002, Clinical Pharmacology , 2001 .
[49] G. Rudnick,et al. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. , 1993, Molecular pharmacology.
[50] G. Rudnick,et al. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. , 1993, Biochimica et biophysica acta.
[51] P. Lecompte,et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. , 1974, American heart journal.
[52] R. Rothman,et al. Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease , 2006, Journal of Pharmacology and Experimental Therapeutics.
[53] B. Largent,et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.
[54] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[55] M. Lopez-Ilasaca. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.
[56] D. Mikhailidis,et al. Longitudinal Effects of Fenfluramine—Phentermine Use , 2007, Angiology.
[57] Christopher J Endres,et al. Noradrenergic and dopaminergic effects of (+)‐amphetamine‐like stimulants in the baboon Papio anubis , 2005, Synapse.
[58] J. Gardin,et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. , 2001, JAMA.
[59] T. Silverstone. Appetite suppressants. A review. , 1992, Drugs.
[60] M. Moskowitz,et al. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[61] J M Feldman,et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. , 1995, Circulation.
[62] S. Garattini,et al. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system , 1986, Appetite.
[63] R. Fossmark,et al. Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.
[64] E. D. de Vries,et al. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. , 1992, Clinical chemistry.
[65] N. Cozzi,et al. Indan Analogs of Fenfluramine and Norfenfluramine Have Reduced Neurotoxic Potential , 1998, Pharmacology Biochemistry and Behavior.
[66] T. Ryan,et al. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. , 2002, American heart journal.
[67] K. Rice,et al. Neurochemical neutralization of methamphetamine with high‐affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse , 2000, Synapse.
[68] M. Maclean,et al. 5‐hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension , 2000, British journal of pharmacology.
[69] M. Humbert,et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension , 2002, Nature Medicine.
[70] D. E. Nichols,et al. Serotonin receptors. , 2008, Chemical reviews.
[71] V. Setola,et al. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. , 2003, Molecular pharmacology.
[72] E. K. Weir,et al. The effect of the anorectic agent, d‐fenfluramine, and its primary metabolite, d‐norfenfluramine, on intact human platelet serotonin uptake and efflux , 2003, Journal of thrombosis and haemostasis : JTH.
[73] R. Wurtman,et al. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines , 1999, The Lancet.
[74] J. Launay,et al. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia. , 1998, American journal of respiratory and critical care medicine.
[75] K. Donnelly. Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases , 2008, Toxicologic pathology.
[76] R. Rothman,et al. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. , 2000, The American journal of cardiology.
[77] P. Rahko,et al. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status , 2007, International Journal of Obesity.
[78] F. Artigas,et al. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium , 2004, Psychopharmacology.
[79] A. Fishman. Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.
[80] P. Celada,et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. , 1992, Journal of affective disorders.
[81] F. Zannad,et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. , 2002, American heart journal.
[82] A. Fray,et al. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. , 2002, European journal of pharmacology.
[83] P. Mantegazza,et al. Effects of mazindol and d-fenfluramine of 5-hydroxytryptamine uptake, storage and metabolism in blood platelets. , 1977, European journal of pharmacology.
[84] Kevin W. Williams,et al. 5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis , 2008, Neuron.